Trial watch: Chemotherapy with immunogenic cell death inducers by Vacchelli, Erika et al.
© 2012 Landes Bioscience.
Do not distribute.
Trial watch
Chemotherapy with immunogenic cell death inducers
Erika Vacchelli,
1,2,3,† Lorenzo Galluzzi,
1,2,3,† Wolf Hervé Fridman,
2,4,5 Jerome Galon,
2,4,6 Catherine Sautès-Fridman,
2,4,7
Eric Tartour,
2,8,9 Laurence Zitvogel
2,10 and Guido Kroemer
1,2,8,11,*
1U848; Villejuif, France;
2INSERM;
3Université Paris-Sud/Paris XI; Paris, France;
4U872; Paris, France;
5Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP; Paris, France;
6Université Pierre et Marie Curie/Paris VI; Paris, France;
7Université Pierre et Marie Curie/Paris VI; Paris, France;
8Pôle de Biologie; Hôpital Européen; Georges Pompidou; AP-HP;
Paris, France;
9Université Paris Descartes; Sorbonne Paris Cité; Paris, France;
10Institut Gustave Roussy; Villejuif, France;
11Université Paris Descartes; Sorbonne Paris Cité;
Metabolomics Platform; Institut Gustave Roussy; Villejuif, France
†These authors contributed equally to this article.
Keywords: autophagy, ATP, calreticulin, HMGB1, HSP70, interferon c
Abbreviations: CRT, calreticulin; DCs, dendritic cells; ER, endoplasmic reticulum; GM-CF, granulocyte-macrophage colony-
stimulating factor; HMGB1, high mobility group box 1; HSPs, heat-shock proteins, ICD, immunogenic cell death; IFNc, interferon c;
IL, interleukin; NSCLC, non-small cell lung cancer; TACE, transhepatic artery chemoembolization; TLR4, Toll-like receptor 4;
Tregs, FOXP3
+ regulatory T cells
The long-established notion that apoptosis would be immuno-
logically silent, and hence it would go unnoticed by the
immune system, if not tolerogenic, and hence it would actively
suppress immune responses, has recently been revisited. In
some instances, indeed, cancer cells undergo apoptosis while
emitting a spatiotemporally-defined combination of signals
that renders them capable of eliciting a long-term protective
antitumor immune response. Importantly, only a few anti-
cancer agents can stimulate such an immunogenic cell death.
These include cyclophosphamide, doxorubicin and oxaliplatin,
which are currently approved by FDA for the treatment of
multiple hematologic and solid malignancies, as well as mito-
xantrone, which is being used in cancer therapy and against
multiple sclerosis. In this Trial Watch, we will review and
discuss the progress of recent (initiated after January 2008)
clinical trials evaluating the off-label use of cyclophosphamide,
doxorubicin, oxaliplatin and mitoxantrone.
Introduction
For a long time, cell death instances were cataloged into either of
two mutually exclusive and diametrically opposed categories:
necrosis, constituting an accidental, pathological, morphologically
nebulous and pro-inflammatory cell death subroutine, and
apoptosis, being a finely regulated, physiological, morphologically
defined and immunologically silent (if not tolerogenic) one.
1-3
During the last decade, this textbook dichotomy has been
revisited, if not invalidated. Thus, multiple pieces of evidence
have accumulated to disconfirm the near-to-dogmatic notions
that necrosis would constitute a merely accidental cell death
mode,
4 that necrosis would fail to exhibit peculiar morphological
manifestations,
5 that necrosis would not be involved in physio-
logical processes,
5 and that apoptosis would always fail to elicit
inflammatory and immune responses.
6
In 2005, Casares et al. first reported that tumor cells
succumbing in vitro to anthracyclines, notably doxorubicin (but
not to other chemotherapeutics such as mitomycin C), can
acquire the capacity to elicit tumor-specific immune responses
when inoculated in syngenic mice.
7 Such immune responses were
found to efficiently protect mice against subsequent re-challenges
with live cells of the same type, de facto resulting in long-term
vaccination.
7 Since then, great efforts have been dedicated to the
elucidation of the molecular and cellular mechanisms that
underlie immunogenic cell death (ICD), leading to the discovery
that ICD relies on the emission of a spatiotemporally-defined
combination of signals by dying cells.
8 Such signals include
(though perhaps are not limited to),
9 (1) the endoplasmic
reticulum (ER) stress-elicited, caspase-dependent pre-apoptotic
co-exposure of the ER chaperons calreticulin (CRT) and ERp57
on the outer leaflet of the plasma membrane;
10-14 (2) the
autophagy-dependent pre-apoptotic secretion of ATP;
15-17
(3) the post-apoptotic release of the non-histone chromatin
binding protein high mobility group box 1 (HMGB1)
18; and
(4) the cell surface exposure or release of heat-shock proteins
(HSPs) including HSP70 and HSP90.
19,20 For ICD to be
productive, i.e., to elicit a long-term protective anticancer
immune response, each of these signals must be properly decoded
by the immune system. Thus, by binding to a hitherto
uncharacterized receptor on the surface of dendritic cells (DCs),
CRT acts as an “eat-me” signal, thereby stimulating the DC-
mediated uptake of apoptotic corpses (and hence tumor
antigens).
10,21 Extracellular ATP not only functions as a “find-
me” signal, thereby stimulating the local recruitment of immune
effector cells,
22 but also binds to purinergic P2RX7 receptors on
the surface of these cells, thereby triggering the activation of the
NLRP3 inflammasome.
17,23 This is a critical step for the induction
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of antitumor immunity, as the inflammasome catalyzes the
proteolytic maturation and secretion of interleukin-1  (IL-1 ), a
cytokine that is required for the adequate polarization of
interferon c (IFNc)-producing CD8
+ T cells.
17 By binding
to Toll-like receptor 4 (TLR4) on DCs, HMGB1 engages a
MYD88-mediated signaling cascade leading to increased tumor
antigen processing and cross-presentation to T cells.
24 Along
similar lines, the presence of HSPs on the surface of dying tumor
cells or in their vicinity promotes the formation of tumor antigen-
HSP complexes that are processed by DCs for T cell cross-
priming more efficiently than tumor antigens alone.
25
So far, only a few anticancer agents have been shown to kill
tumor cells while inducing all these phenomena in the correct
spatiotemporal order, thus eliciting bona fide ICD. These include
some types of radiotherapy and only four chemotherapeutics: the
DNA alkylating compound cyclophosphamide, the anthracyclines
doxorubicin and mitoxantrone and the platinum derivative
oxaliplatin.
7,10,26-28 Importantly, anticancer agents failing to elicit
one (or more) of the abovementioned sine quibus non are
intrinsically unable to induce ICD, a defect that, at least in some
instances, can be restored by targeted pharmacological interven-
tions. Thus, cisplatin (a platinum derivative structurally related to
oxaliplatin) alone fails to elicit the pre-apoptotic exposure of CRT,
yet becomes able to do so when combined with ER stressors such
as thapsigargin, rendering cisplatin-induced cell death immuno-
genic.
29 Recently, the histone deacetylase inhibitor vorinostat has
been found to trigger CRT exposure in childhood brain tumor
cell lines, in vitro.
30 However, the true potential of vorinostat as
an inducer of ICD remain unexplored, and actually contrasting
reports can be found in the literature on its immunostimulatory
vs. immunosuppressive effects.
31-33
At present, cyclophosphamide, doxorubicin and oxaliplatin are
approved by FDA for the treatment of multiple malignancies
(Table 1). Mitoxantrone is mainly used for a cancer-unrelated
indication, multiple sclerosis, even though FDA has also approved
mitoxantrone-containing combination regimens for the treatment
of acute leukemia, non-Hodgkin’s lymphoma, breast and prostate
cancer (Table 1). In this Trial Watch, we will discuss the progress
of recent (started after January 2008) clinical studies evaluating
the efficacy—as off-label medications—of the only four che-
motherapeutics that so far have been described as bona fide
ICD inducers.
Cyclophosphamide
Cyclophosphamide is a DNA alkylating agent belonging to the
family of nitrogen mustards.
34 Upon conversion into 4-hydro-
xycyclophosphamide by hepatic mixed function oxidases, cyclo-
phosphamide becomes able to add an alkyl group (CnH2n+1)t o
the nitrogen atom at position 7 in the imidazole group of purine
DNA bases, thereby acquiring cytotoxic properties.
34 Although
initially conceived as a cancer-selective drug (due to a presumed
cancer cell-specific mechanism of activation), cyclophosphamide
has rapidly turned out to be cytotoxic for multiple cell types,
including immune cells.
34 Owing to this pharmacodynamic
profile, cyclophosphamide has soon entered the clinical practice
not only as an anticancer agent for the treatment of some forms
of lymphoma, leukemia and solid tumors (Table 1), but also for
the therapy of non-neoplastic autoimmune diseases, including
systemic lupus erythematosus, rheumatoid arthritis and multiple
sclerosis.
35 Still, recent data indicate that, at odds with the
immunosuppressive properties of cyclophosphamide at high
doses, metronomic cyclophosphamide regimens exert profound
immunostimulatory effects,
36 for instance by selectively deplet-
ing or inhibiting FOXP3
+ regulatory T cells (Tregs).
37 Such
immunostimulatory properties appear to at least contribute to, if
not entirely explain, the therapeutic success of cyclophosphamide
as an anticancer agent.
34
In the last three years (2009–2011), a consistent number of
trials aimed at testing the clinical benefits of cyclophosphamide
in cancer patients has been terminated and the corresponding
results published in high impact scientific journals (source
http://www.ncbi.nlm.nih.gov/sites/entrez). In most cases, these
clinical studies investigated—in oncological settings in which
cyclophosphamide is approved by FDA—either how variations
in dosage and/or schedule affect safety and efficacy or whether
the combination between cyclophosphamide and other chemo-
therapeutics improves the therapeutic outcome.
38-42 In addition,
cyclophosphamide-based combination regimens have been tested
in both low- and intermediate-risk rhabdomyosarcoma pediatric
patients, in both cases providing no significant benefits as
compared with the control arm.
43,44
At present, there are around 530 open clinical trials, all phases
confounded, that test the efficacy of cyclophosphamide in onco-
logical indications (source www.clinicaltrials.gov). Approximately
Table1. Currently approved indications for immunogenic chemotherapy*
Drug Indications
Cyclophosphamide
ALL, AML, breast cancer, CLL, CML, lupus nephritis, lymphoma, multiple myeloma, mycosis fungoides, neuroblastoma,
nephrotic syndrome, ovarian cancer, retinoblastoma.
Doxorubicin
ALL, AML, breast cancer, bronchogenic carcinoma, cervical carcinoma, gastric carcinoma, germ cell tumors, hepatic
carcinoma, HNC, lymphoma, mesothelioma, multiple myeloma, neuroblastoma, ovarian carcinoma, pancreatic
carcinoma, prostate cancer, SCLC, soft tissue and bone sarcomas, thyroid carcinoma, transitional cell bladder
carcinoma, uterine carcinoma, Wilms' tumor.
Oxaliplatin Metastatic colorectal cancer, ovarian cancer.
Mitoxantrone Acute leukemia, breast cancer, NHL, multiple sclerosis, prostate cancer.
Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; HNC,
head and neck cancer; NHL, non-Hodgkin’s lymphoma; SCLC, small cell lung cancer. *by FDA or European Medicines Agency (EMA) at the day of submission.
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430 (320–355 phase I-II, 75–110 phase III-IV) of these studies are
performed in clinical scenarios that correspond or overlap with
cyclophosphamide indications. In addition, cyclophosphamide is
being evaluated, alone or in combination with other anticancer
agents, in several off-label settings (Table 2). Around 10% of these
latter trials are advanced ones (phase III-IV), including four studies
that test cyclophosphamide-including combination regimens in
brain cancer—notably atypical teratoid/rhabdoid tumors, choroid
plexus tumors and ependymoma—patients (NCT01014767,
NCT01096368, NCT00683319, NCT00653068), as well as two
studies that investigate the combination of cyclophosphamide with
cancer vaccines in non-small cell lung cancer (NSCLC) patients
(NCT01015443, NCT01444118). A consistent fraction of early
trials (phase I-II) is testing whether cyclophosphamide (most often
in association with the nucleoside analog fludarabine or with
immunostimulatory interventions such as the administration of
Table2. Main trends of clinical trials evaluating the effects of cyclophosphamide as an off-label medication for cancer patients*
Location Tumor type Trials* Phase Notes
Early clinical trials (phase I-II)
Brain
Choroid plexus carcinoma 1 II
Often combined with platinum-containing regimens,
EGFR inhibitors, etoposide or peptide-based vaccines.
Embryonic brain tumors 1 II
Ependymoma 1 II
Glioblastoma 2 I-II
Medulloblastoma 2 II
Colorectal tract CRC 5 I-II Combined with different immunostimulatory approaches.
Connective tissue
Osteosarcoma 1 II Combined with sirolimus.
Rhabdomyosarcoma 2 II Combined with mAbs.
Epidermis Melanoma 20 I-II
Often combined with fludarabine or immunostimulatory
interventions.
Gastrointestinal system Pancreatic cancer 5 II Often combined with GM-CSF-based vaccines.
Hematological tumors
ATL 1 II Combined with fludarabine.
MDS 3 II
Often combined with ATG, fludarabine and stem cell
transplantation.
T-PLL 1 II Combined with fludarabine and immunotherapy.
HNC SCCHN 2 I
Combined with fludarabine and/or immunostimulatory
interventions.
Kidney Advanced or metastatic renal cancer 2 I-II
Combined with allogeneic HSCT, immunostimulatory
interventions or everolimus.
Lung
Metastatic lung cancer 1 II Combined with cancer vaccines.
NSCLC 3 I-II Combined with cancer vaccines.
PPB 1 II
Combined with dactinomycin, doxorubicin, ifosfamide
and vincristine.
SCLC 1 II In the context of the PCDE regimen.
Mesothelioma - 2 I Combined with immunotherapy.
Reproductive tract Prostate cancer 5 I-II Often combined with immunostimulatory approaches.
Thymus Thymoma 2 I-II
Combined with belinostat, cetuximab, cisplatin or
doxorubicin.
Advanced clinical trials(phase III-IV)
Brain
AT/RT 1 III
Combined with cisplatin, etoposide, folinic acid,
methotrexate and vincristine.
Choroid plexus tumors 1 III
Combined with platinum-containing anticancer drugs,
etoposide and vincristine.
Ependymoma 2 III
Always combined with platinum-containing anticancer
drugs and vincristine.
Lung NSCLC 2 III Always in combination with cancer vaccines.
Abbreviations: ATG, thymoglobulin; ATL, adult T-cell leukemia; AT/RT, atypical teratoid/rhabdoid tumor; CRC, colorectal cancer; EGFR, epidermal growth
factor receptor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HNC, head and neck cancer; HSCT, hematopoietic stem cell transplantation;
mAb, monoclonal antibody; MDS, myelodysplastic syndrome; NSCLC, non-small cell lung cancer; PCDE, cisplatin, cyclophosphamide, doxorubicin, etoposide;
PPB, pleuropulmonary blastoma; SCCHN, squamous cell cancer of the head and neck; SCLC, small cell lung carcinoma; T-PLL, T-cell prolymphocytic leukemia.
*started after January, 1st 2008 and not completed or terminated at the day of submission.
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IL-2, DC-based vaccines or autologous T cell transfers) is safe
and efficient in melanoma patients (NCT01005745,
NCT00863330, NCT01339663, NCT01106235,
NCT01435499, NCT00683670, NCT00937625,
NCT00871481, NCT00722098, NCT01455259,
NCT00604136, NCT00846833, NCT00910650,
NCT01319565, NCT01236573, NCT01468818,
NCT01369875, NCT01369888, NCT01271907,
NCT01118091). The combination between cyclophosphamide
and granulocyte-macrophage colony-stimulating factor (GM-CSF)-
based vaccines (including GVAX) in the context of pancreatic
cancer is being investigated by many groups (NCT01468870,
NCT01417000, NCT01088789, NCT00727441,
NCT01021800). Along similar lines, cyclophosphamide is currently
being tested together with immunostimulatory approaches (includ-
ing anti-PD1 and anti-OX40 monoclonal antibodies)
45 against
colorectal (NCT01064375, NCT00785122, NCT01462513,
NCT00986518) and prostate cancer (NCT01303705,
NCT01093183, NCT01420965, NCT01140373,
NCT00753220). Besides these main trends, there are several other
oncological indications for which the putative benefits of cyclopho-
sphamide are being investigated in phase I-II clinical trials (Table 2),
including (but not limited to) glioblastoma (NCT01403285,
NCT01454596), myelodysplastic syndrome (NCT01255319,
NCT00604201, NCT01174108), medulloblastoma
(NCT00867178, NCT01356290), NSCLC (NCT00960115,
NCT01159288), renal cancer (NCT01462214, NCT00923845),
rhabdomyosarcoma (NCT01222715, NCT01055314) and thy-
moma (NCT01100944, NCT01025089).
Taken together, these observations clearly suggest that
cyclophosphamide is the subject of an intense wave of clinical
investigation, most often owing to its multifaceted immuno-
stimulatory functions. Importantly, while many clinical studies
demonstrate that metronomic cyclophosphamide leads to
improved T cell effector functions,
36,46-48 its long-term clinical
efficacy as well as its added value as compared with other
strategies for depleting/inhibiting Tregs remain a matter of
debate.
49-52 The results from ongoing clinical trials will help to
clarify this issue.
Doxorubicin
Doxorubicin (also known as adriamycin) is a natural compound
belonging to the class of anthracycline antibiotics that functions as
a DNA intercalating agent.
53 As such, it impedes the progression
of topoisomerase II along DNA, de facto blocking the resolution
of quaternary DNA structures (while inducing an accumulation of
topoisomerase-introduced single-strand breaks) and hence inhibit-
ing DNA replication (and to a lesser degree transcription).
54
Doxorubicin is associated with common and relatively mild side
effects, including nausea, vomiting and alopecia, as well as with
dose-limiting cardiotoxicity, presumably due to the generation
of mitochondriotoxic reactive oxygen species (ROS) upon the
interaction between doxorubicin and iron.
55 Still, doxorubicin
(alone or in combination with other chemotherapeutics including
cyclophosphamide) is widely used for the treatment of some forms
of leukemia, Hodgkin’s lymphoma as well as a plethora of solid
neoplasms, including (but not limited to) bladder, breast,
stomach, lung, ovarian and thyroid cancer (Table 1). Recent
preclinical results from several laboratories worldwide indicate that
doxorubicin not only triggers ICD but stimulates various aspects
of the immune response against cancer.
36
During the last triennium, only a few doxorubicin-based
clinical trials have been reported in major scientific journals
(source www.clinicaltrials.gov), focusing on the optimization of
dosage and schedule for FDA-approved indications.
39,40 Now,
approximately 370 open clinical trials, all phases confounded, are
investigating the efficacy of doxorubicin against various types of
cancer (source www.clinicaltrials.gov). Among these, some 270
trials (190–220 phase I-II, 50–80 phase III-IV) are performed in
settings that match or exhibit some degree of overlaps with the
FDA-approved indications of doxorubicin. Moreover, doxorubi-
cin is being tested, alone or combined with other chemother-
apeutics, as an off-label medication in multiple clinical scenarios
(Table 3). Indicatively, 20% of these latter trials are advanced
ones, including a large fraction of studies in which doxorubicin is
tested for the neoadjuvant treatment of liver cancer, either in
combination with chemotherapy or coupled to maneuvers for
maximizing efficacy such as transhepatic artery chemoemboliza-
tion (TACE) (NCT01387932, NCT01332669, NCT00617981,
NCT00936689, NCT01327521, NCT00807300,
NCT01015833, NCT01324076, NCT01004978,
NCT00980460). Other advanced trials explore the use of doxo-
rubicin against lymphoma (NCT00854568, NCT00722137),
multiple myeloma (NCT00734877, NCT00670631) and endo-
metrial cancer (NCT00883116, NCT00698620). Along similar
lines, a consistent fraction of doxorubicin-based early clinical trials
(Table 3) is performed on patients affected by liver cancer (often
in association with TACE or the anti-angiogenic compound
sorafenib) (NCT00988195, NCT01125020, NCT00844883,
NCT00877071, NCT01259024, NCT01033578,
NCT01116635, NCT01272557, NCT00855218,
NCT00990860, NCT00919009, NCT01381211,
NCT00857805, NCT01009801, NCT01281943,
NCT01011010, NCT00949182, NCT00956930), multiple
myeloma (near-to-always in combination with the proteasomal
inhibitor bortezomib) (NCT00720174, NCT00750815,
NCT01215344, NCT00617591, NCT01246063,
NCT00985907, NCT00863174, NCT00849251,
NCT01394354, NCT00706953, NCT01177683,
NCT00724568, NCT00872521, NCT01160484,
NCT01101594, NCT01365559, NCT00925821,
NCT01255514. NCT01371227, NCT00744354,
NCT00814541, NCT01078441. NCT00742404,
NCT01055301, NCT01328236) and endometrial cancer
(NCT01100359, NCT00739830). In addition, the safety and
efficacy of doxorubicin (in most cases combined with other
chemotherapeutics) are being investigated in diffuse large B-cell
lymphoma (NCT01361191, NCT01087424), osteosarcoma
(NCT01459484, NCT00691236, NCT01258634), thymoma
(NCT01025089, NCT01100944) and urothelial cancer patients
(NCT01093066, NCT00808639).
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In spite of the fact that both cyclophosphamide and doxorubicin
have been recently ascribed with a consistent immunostimulatory
potential, in particular when employed in metronomic regimens,
36
only for the former this notion appears to translate into a clinical
interest. The reasons underlying this trend remain unclear, yet may
be related to toxicological and/or economical factors.
Oxaliplatin
Oxaliplatin is a third-generation platinum coordination complex
originally developed in the 1990s in the attempt to circumvent
the common resistance of tumors against first- (cisplatin) and
second-generation (carboplatin) compounds.
56 The molecular
mechanisms whereby platinum derivatives, especially oxaliplatin,
exert cytotoxic effects against cancer cells are complex and surely
overtake their capacity to generate DNA adducts and to activate
the pro-apoptotic transcription factor p53.
57-60 Although cisplatin-
refractory neoplasms are largely considered to be responsive to
oxaliplatin, clinical data suggest that there may be some degree of
cross-resistance.
61 Since 1996 in Europe and 2002 in the US,
oxaliplatin is clinically employed for the treatment of colorectal
cancer in combination with 5-fluorouracil and folinic acid (the
FOLFOX protocol) (Table 1). Besides inducing ICD, oxaliplatin
reportedly inhibits the expression of programmed death ligand 2
(PD-L2), thereby limiting immunosuppression by both DCs and
tumor cells.
62
Table3. Main trends of clinical trials evaluating the effects of doxorubicin as an off-label medication for cancer patients*
Location Tumor type Trials* Phase Notes
Early clinical trials (phase I-II)
Connective tissue
MFH 2 I/II Combined with mAb and chemotherapeutics.
Osteosarcoma 4 II Always combined with cisplatin.
Rhabdomyosarcoma 1 II Combined with mAb and chemotherapeutics.
Hematological tumors
DLBCL 2 II Within the R-MEGACHOP or R-MiniCHOP regimen.
Leukemia 1 II Combined with bortezomib and dexamethasone.
Plasma cell neoplasms
(including MM)
23 I-II
Often combined with bortezomib, cyclophosphamide and
dexamethasone.
Epidermis Melanoma 2 I-II In the context of TACE.
Liver
HCC 14 I-II Often combined with sorafenib and TACE.
Non-specified 4 I-II Often combined with mitomycin C and sorafenib.
Lung
NSCLC 1 II Combined with carboplatin.
Pleural mesothelioma 2 II Always combined with cisplatin.
PPB 1 II
Combined with cyclophosphamide, dactinomycin, ifosfamide
and vincristine.
Reproductive tract
Endometrial cancer 1 II
Often combined with hormonotherapy.
Prostate cancer 2 II
Thymus Thymoma 2 I-II
Combined with belinostat, cetuximab, cisplatin and
cyclophosphamide.
Urogenital tract
Bladder cancer 1 II
In the context of the MVAC regimen.
Urothelial tract 3 II
Advanced clinical trials(phase III-IV)
Brain
Choroid plexus tumors 1 III
Always combined with cyclophosphamide and etoposide.
Others 1 III
Hematological tumors
Lymphomas 2 III Within the CHOP or R-CHOP regimen.
MM 2 III Within the M-VTD-PACE or DPACE regimen.
Liver
HCC 6 III-IV In the context of TACE.
Others 4 III Combined with other chemotherapeutics.
Reproductive tract Endometrial cancer 2 III Alone or combined with cisplatin, filgrastim or paclitaxel.
Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; DLBCL, diffuse large B-cell lymphoma; DPACE, dexamethasone, cisplatin,
doxorubicin, cyclophosphamide, etoposide; HCC, hepatocellular carcinoma; mAb, monoclonal antibody; M-VTD-PACE, bortezomib, cisplatin, cyclopho-
sphamide, dexamethasone, etoposide, melphalan, thalidomide; MFH, malignant fibrous histiocytoma; MM, multiple myeloma; MVAC, doxorubicin, cisplatin,
methotrexate, vinblastine; NSCLC, non-small cell lung cancer; PPB, pleuropulmonary blastoma; R-CHOP, cyclophosphamide, doxorubicin, vincristine,
prednisone, rituximab; R-MEGACHOP, cyclophosphamide, etoposide, ifosfamide, prednisone, rituximab, vincristine; R-MiniCHOP, cyclophosphamide,
prednisone, rituximab, vincristine; TACE, transhepatic arterial chemoembolization. *started after January, 1st 2008 and not completed or terminated at the
day of submission.
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The triennium 2009–2011 has witnessed several high impact
publications on the clinical profile of oxaliplatin (source www.
clinicaltrials.gov). On one hand, several studies have evaluated
dosage, schedule and the possible combination of oxaliplatin with
other chemotherapeutics for the therapy of colorectal cancer.
63-65
On the other hand, multiple reports suggest that oxaliplatin may
constitute a valuable therapeutic option for a wide range of
tumors, including NSCLC, pancreatic, biliary tract, gall bladder
and ampullary cancer.
66-72
Not less than 330 ongoing clinical trials, all phases confounded,
currently investigate the efficacy of oxaliplatin in cancer patients
(source www.clinicaltrials.gov). Approximately 190 (140–160
phase I-II, 30–50 phase III-IV) of these studies involve colorectal
cancer patients. In addition, there are some 140 clinical trials that
evaluate the potential of oxaliplatin, alone or combined with other
interventions, as an off-label medication (Table 4). Among 12
advanced clinical trials, three investigate the efficacy of oxaliplatin
plus gemcitabine (a nucleoside analog) in biliary tract cancer
patients (NCT01313377, NCT01470443, NCT01149122).
In addition, there are four phase III trials evaluating the
benefits of oxaliplatin (combined with the nucleoside analog
5-fluorouracil or with its pro-drug capecitabine) against gastric
cancer (NCT01470742, NCT00941655, NCT00718354,
NCT00680901), and three phase III trials in which oxaliplatin
(associated to nucleoside analogs) is tested in pancreatic cancer
patients (NCT01314027, NCT01362582, NCT01121848).
This trend is fully reflected in early clinical studies, including
10 trials on biliary tract cancer patients (NCT01267344,
NCT01180153, NCT01234051, NCT01127555,
NCT00881504, NCT01389414, NCT01247337,
NCT00713687, NCT00779454, NCT01206049), 50 studies
on esophageal and gastric cancer patients (NCT00711243,
NCT01307956, NCT01191697, NCT00982592,
NCT01246960, NCT01386346, NCT01443065,
NCT00849615, NCT01333033, NCT01295086,
NCT01362127, NCT01262482, NCT00673673,
NCT00667420, NCT00816543, NCT00861094,
NCT01467921, NCT01248299, NCT00711412,
NCT00985556, NCT00961077, NCT01471132,
NCT01364493, NCT01138904, NCT00952003,
NCT01359397, NCT01396707, NCT01049620,
NCT01216644, NCT01090505, NCT01331928,
NCT01130805, NCT01129310, NCT00767377,
NCT01364376, NCT00733616, NCT01283204,
NCT01130337, NCT01070290, NCT01106066,
NCT01160419, NCT01100801, NCT01197118,
NCT01351038, NCT01472029, NCT01206218,
NCT00854854, NCT01208103, NCT01202409,
NCT01422993). In addition, oxaliplatin is being investigated
(most often in combination with 5-fluorouracil) in 14 distinct
clinical trials enrolling pancreatic cancer patients
(NCT00690300, NCT01473303, NCT00707278,
NCT01413022, NCT01397019, NCT01359007,
NCT00786058, NCT01446458, NCT01063192,
NCT00728000, NCT01394120, NCT01415713,
NCT01209962, NCT01454180) as well as in eight studies
based on prostate cancer patients (NCT01338792,
NCT00871169, NCT01042028, NCT00636883,
NCT00602602, NCT01048320, NCT00609336,
NCT01383538).
Thus, there appears to be a consistent interest in the clinical
properties of oxaliplatin, in particular in the context of
combination regimens that include nucleoside analogs. Results
from recently terminated clinical trials suggest that oxaliplatin
may be beneficial for a wide range of solid tumors. Although it is
too early to discern whether this depends or not on the ability of
Table4. Main trends of clinical trials evaluating the effects of oxaliplatin as an off-label medication for cancer patients*
Location Tumor type Trials* Phase Notes
Early clinical trials (phase I-II)
Breast Breast cancer 5 II In association with nucleoside analogs, docetaxel or trastuzumab.
Gastrointestinal system
Biliary tract cancer 9 II
Often combined with nucleoside analogs, including 5-FU,
capecitabine or gemcitabine.
Esophageal cancer 19 I-II
Gastric cancer 42 I-II
Pancreatic cancer 14 I-II
Hematological tumors Lymphomas 6 I-II Combined with nucleoside analogs and/or glucocorticoids.
Liver HCC 6 I-II Often combined with nucleoside analogs.
Lung NSCLC 3 II Combined with docetaxel or pemetrexed.
Reproductive tract Prostate cancer 8 I-II Combined with nucleoside analogs or EGFR inhibitors.
Advanced clinical trials(phase III-IV)
Gastrointestinal system
Biliary tract cancer 3 III Always combined with gemcitabine.
Gastric cancer 4 III Combined with 5-FU or capecitabine.
Pancreatic cancer 3 III Combined with 5-FU or gemcitabine.
Abbreviations: 5-FU, 5-fluorouracil; EGFR, epidermal growth factor receptor; HCC, hepatocellular carcinoma; NSCLC, non-small cell lung cancer. *started after
January, 1st 2008 and not completed or terminated at the day of submission.
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oxaliplatin to trigger ICD, the oncological indications for which
oxaliplatin is approved by FDA may soon increase.
Mitoxantrone
Similar to doxorubicin, mitoxantrone (a synthetic anthracene-
dione first developed in the mid 1980s) operates as an
intercalating agent and inhibits topoisomerase II, thus impairing
DNA replication, transcription and repair.
73 Mitoxantrone shares
doxorubicin’s spectrum of adverse reactions, including immuno-
suppression and a dose-limiting cardiotoxicity that can develop
during treatment as well as years after discontinuation.
74 Due to
its immunosuppressive properties, mitoxantrone is successfully
used in the clinic to limit the frequency of relapse and slow the
progression of several variants of multiple sclerosis.
75 In addition,
the FDA has approved mitoxantrone, alone or in combination
with other chemotherapeutics or prednisone, for the therapy of
acute leukemia, non-Hodgkin’s lymphoma, breast and prostate
cancer (Table 1).
Results from recently terminated (2009–2011), randomized
clinical trials confirm that mitoxantrone provides clinical benefits
in children with acute lymphoblastic leukemia but suggest that
cabazitaxel plus prednisone may be superior than mitoxantrone
plus prednisone for the treatment of metastatic castration-resistant
prostate cancer that progresses upon docetaxel-based therapy.
76,77
Now, 36 open clinical trials are studying the efficacy of
mitoxantrone against distinct types of cancer (source www.
clinicaltrials.gov). Of these, 29 (23 phase I-II, 6 phase III-IV) are
performed in settings that match mitoxantrone FDA-approved
indications. Moreover, the safety and efficacy of mitoxantrone,
alone or combined with other anticancer agents, are being
evaluated in a few off-label scenarios (Table 5). Among these
latter studies, one single advanced (phase III) trial is testing the
association between mitoxantrone (or other chemotherapeutics)
and the anti-CD20 monoclonal antibody rituximab in follicular
lymphoma patients (NCT00774826). Along similar lines,
mitoxantrone is currently being investigated in five early clinical
trials for its efficacy against various types of lymphoma and T-cell
prolymphocytic leukemia (NCT00901927, NCT01133158,
NCT01186640, NCT01144403, NCT00712582).
The reasons whereby mitoxantrone—at odds with doxorubicin,
which is also an anthracycline—is not the subject of an intense
wave of clinical studies as an off label medication remain unclear.
Perhaps, this may be due to the fact that while doxorubicin-based
metronomic regimens have already been developed (and shown
not only to be devoid of immunosuppressive effects but also to
actively stimulate immunity),
36 the same does not hold true for
mitoxantrone, whose preferential toxicity for immune cells de
facto underlies its anticancer potential against lymphoma and
leukemia.
Concluding Remarks
For a long time, the immune system has been viewed as a rather
passive bystander of cancer, so much that even the National
Cancer Institute recommended testing the antineoplastic potential
of new molecules in immunodeficient murine models. Now, it
has become clear that the immune system plays a critical role not
only during early oncogenesis, by keeping under surveillance
transformed and potentially tumorigenic cells, but also during the
response of established malignancies to therapy.
36,78-80 On one
hand, indicators of an ongoing immune response, such as the
extent or the composition of the intratumoral infiltrate, as well as
polymorphisms in genes that code for immune modulators have
been correlated with the outcome of therapy. On the other hand,
several anticancer compounds (be they conventional chemother-
apeutics or targeted agents) have recently been shown to stimulate
antitumor immunity.
36
Among several molecular and cellular circuitries whereby
anticancer agents can trigger tumor-specific immune responses
stands the induction of ICD, a functionally peculiar type of
apoptosis that is associated with a spatiotemporally defined
combination of immunogenic signals.
8 In spite of the fact that the
existence of ICD has been acknowledged only a few years ago,
10
some agents that are capable of triggering ICD have already been
identified, including cyclophosphamide, doxorubicin, oxaliplatin
and mitoxantrone. All these compounds are approved by FDA for
cancer therapy, have been successfully used in the clinic for several
years, and are now being investigated for their utility in a range
of off-label applications. It is tempting to speculate—but cannot
be formally demonstrated—that part of the clinical success of
these chemicals is due to their ability to trigger ICD. Irrespective
of these considerations, it will be interesting to see whether
cyclophosphamide, doxorubicin, oxaliplatin and mitoxantrone
will be approved for additional cancer-related indications, as well
as if novel inducers of ICD will be identified and will make their
way from the bench to the bedside. In addition, it remains to be
seen whether ICD inducers may be advantageously combined
with non-immunogenic conventional chemotherapeutics, targeted
anticancer agents and/or immunostimulatory strategies.
Table5. Main trends of clinical trials evaluating the efficacy of mitoxantrone as an off-label medication for cancer patients*
Location Tumor type Trials* Phase Notes
Early clinical trials (phase I-II)
Hematological tumors
Lymphoma 4 II Always in association with rituximab.
T-PLL 1 II In association with alemtuzumab, cyclophosphamide and fludarabine.
Advanced clinical trials(phase III-IV)
Hematological tumors Follicular lymphoma 1 III In association with rituximab and fludarabine.
Abbreviations: T-PLL, T-cell prolymphocytic leukemia. *n° of trials started after January, 1st 2008 and not completed or terminated at the day of submission.
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